Immunome (IMNM) Receivables - Other (2022 - 2023)
Immunome's (IMNM) quarterly Receivables - Other came in at $289000.0 in Q4 2023, down 65.88% YoY from $847000.0 in Q4 2022, and up 38.94% on a QoQ basis from $208000.0 in Q2 2023.
Immunome (IMNM) Receivables - Other (2022 - 2023) Analysis & Trends
Immunome (IMNM) has 2 years of Receivables - Other data on file, last reported at $289000.0 in Q4 2023.
- Quarterly Receivables - Other fell 65.88% year-over-year to $289000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $289000.0 (down 65.88% YoY) and the FY2023 annual result came in at $289000.0, down 65.88% from the prior year.
- Receivables - Other climbed to $289000.0 in Q4 2023, from $208000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $847000.0 in Q3 2022 to a low of $208000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 289,000.00 |
| Dec 31, 2023 | 289,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Mar 31, 2023 | 821,000.00 |
| Mar 31, 2023 | 821,000.00 |
| Dec 31, 2022 | 847,000.00 |
| Dec 31, 2022 | 847,000.00 |
| Sep 30, 2022 | 847,000.00 |
| Sep 30, 2022 | 847,000.00 |
| Jun 30, 2022 | 800,000.00 |
| Jun 30, 2022 | 800,000.00 |